Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Gavreto is the brand name for pralsetinib, an oral targeted cancer medicine. It inhibits the RET kinase involved in certain tumors with a RET gene fusion. In the U.S., it is used for specified RET fusion-positive lung and thyroid cancers.
read more about gavreto ...Gavreto treats adults with metastatic RET fusion-positive non-small cell lung cancer identified by an approved test. It also treats adults and patients age 12 or older with advanced or metastatic RET fusion-positive thyroid cancer that requires systemic therapy and is resistant to radioactive iodine when that treatment is appropriate. A tumor test helps determine whether the cancer has the RET fusion needed for treatment selection.
Some cancers carry a RET gene fusion that drives abnormal growth signals. Pralsetinib blocks RET kinase activity and can slow the growth of these cancer cells. The medicine is selected according to the tumor type and its test results.
Gavreto comes as capsules taken by mouth once daily. The labeled dose is taken on an empty stomach, with no food for at least two hours before and one hour after a dose. A cancer care team may adjust or pause treatment if adverse effects develop.
Common adverse effects include muscle or joint pain, constipation, diarrhea, fatigue, swelling, and high blood pressure. Gavreto carries a boxed warning for serious infections that may require hospitalization or cause death. New fever, cough, breathing trouble, or other signs of infection should be reported promptly; the care team also monitors blood pressure and liver tests.
Yes. Treatment selection depends on finding a RET gene fusion in the cancer.
No. Take it on an empty stomach as directed on the prescription label.
Yes. Contact the cancer care team promptly if signs of infection develop.
No. Its thyroid cancer indication has specific RET fusion, age, disease stage, and treatment criteria.
Dosing For RET+ NSCLC Treatment | GAVRETO? (pralsetinib) for HCPs. Rigel Pharmaceuticals. https://www.gavreto-hcp.com/mnsclc/dosing-and-administration/dosing/. Date Accessed October 6, 2026.
GAVRETO- pralsetinib capsule. DailyMed (National Library of Medicine). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16edd46e-28b8-f06d-e063-6394a90ae31b. Date Accessed October 6, 2026.
Pralsetinib. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a620057.html. Date Accessed October 6, 2026.
Pralsetinib. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/pralsetinib. Date Accessed October 6, 2026.
Pralsetinib Oral Capsules. Cleveland Clinic. https://my.clevelandclinic.org/health/drugs/23883-pralsetinib-oral-capsules. Date Accessed October 6, 2026.